Clearline Capital’s Myriad Genetics MYGN Stock Holding History

Clearline Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-41,334	Closed	-$689K	–	65
2016 Q4	$689K	Buy	+41,334	New	+$748K	0.31%	37

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Clearline Capital's MYGN Position: Q1 2017 in Review

Clearline Capital sold out of Myriad Genetics (MYGN) in Q1 2017, closing a stake of 41,334 shares — an estimated $689K sold.

Clearline Capital first reported a position in MYGN in Q4 2016 and held it in 1 quarter. The position peaked at $689K in Q4 2016. 233 funds tracked by Wall St. Rank hold MYGN as of Q1 2017.

Clearline Capital reported no remaining Myriad Genetics position as of Q1 2017 after selling out during the quarter.
Clearline Capital sold 41,334 Myriad Genetics shares in Q1 2017, an estimated $689K.
Clearline Capital first reported a position in Myriad Genetics in Q4 2016 and held it in 1 quarter.
Clearline Capital's Myriad Genetics position peaked at $689K in Q4 2016.
233 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2017.

Based on Clearline Capital's 13F filing for Q1 2017, filed 12 May 2017.